Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1141 ARTÍCULOS , VIENDO DEL 691 AL 705

Neurodegenerative disease phenotypes in carriers of MAPT p.A152T, a risk factor for frontotemporal dementia spectrum disorders and Alzheimer disease

Lee SE, Tartaglia MC, Yener G, Genç S, Seeley WW, Sanchez-Juan P, Moreno F, Mendez MF, Klein E, Rademakers R, López de Munain A, Combarros O, Kramer JH, Kenet RO, Boxer AL, Geschwind MD, Gorno-Tempini ML, Karydas AM, Rabinovici GD, Coppola G, Geschwind DH, Miller BL.

Alzheimer Dis Assoc Disord. 2013 Oct-Dec;27(4):302-9. doi: 10.1097/WAD.0b013e31828cc357.

Agitation and aggression in people with Alzheimer's disease

Ballard C, Corbett A.

Curr Opin Psychiatry. 2013 May;26(3):252-9. doi: 10.1097/YCO.0b013e32835f414b.

Benzodiazepine and dementia: a time for reflection

Bocti C, Roy-Desruisseaux J, Hudon C, Roberge P.

Maturitas. 2013 Jun;75(2):105-6. doi: 10.1016/j.maturitas.2013.03.001. Epub 2013 Mar 26.

The mini-Kingston Standardized Cognitive Assessment

Hopkins RW, Kilik LA.

Am J Alzheimers Dis Other Demen. 2013 May;28(3):239-44. doi: 10.1177/1533317513481095. Epub 2013 Mar 28.

Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects

Rodrigue KM, Rieck JR, Kennedy KM, Devous MD Sr, Diaz-Arrastia R, Park DC.

JAMA Neurol. 2013 May;70(5):600-6. doi: 10.1001/jamaneurol.2013.1342.

Test Your Memory (TYM) as a screening instrument in clinical practice - the Polish validation study

Szczesniak D, Wojtynska R, Rymaszewska J.

Aging Ment Health. 2013;17(7):863-8. doi: 10.1080/13607863.2013.784957. Epub 2013 Apr 5.

"Will I get Alzheimer disease?" when cognitively normal patients ask to be tested for Alzheimer disease

Snider BJ, Buckles VD.

Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):470-4. doi: 10.1212/01.CON.0000429171.50686.07.

Genetic testing for early-onset Alzheimer disease

Tsao JW.

Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):475-9. doi: 10.1212/01.CON.0000429170.50686.4e.

Patient management problem

Pierce A.

Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):519-37. doi: 10.1212/01.CON.0000429166.97320.81.

[Assessment of mild cognitive impairment and dementia in epidemiologic studies. An overview on the current state of research in Germany]

Then FS, Luck T, Jacobi F, Berger K, Weyerer S, Grabe HJ, Busch MA, Wagner M, Riedel-Heller SG.

Psychiatr Prax. 2013 May;40(4):183-91. doi: 10.1055/s-0033-1343138. Epub 2013 Apr 5.

Psychosis of Alzheimer disease: prevalence, incidence, persistence, risk factors, and mortality

Vilalta-Franch J, López-Pousa S, Calvó-Perxas L, Garre-Olmo J.

Am J Geriatr Psychiatry. 2013 Nov;21(11):1135-43. doi: 10.1016/j.jagp.2013.01.051. Epub 2013 Feb 6.

Sundowning syndrome: a possible marker of frailty in Alzheimer's disease?

Ferrazzoli D, Sica F, Sancesario G.

CNS Neurol Disord Drug Targets. 2013 Jun;12(4):525-8. doi: 10.2174/18715273113129990065.

Emerging roles for intersectin (ITSN) in regulating signaling and disease pathways

Hunter MP, Russo A, O'Bryan JP.

Int J Mol Sci. 2013 Apr 10;14(4):7829-52. doi: 10.3390/ijms14047829.

MR imaging features of amyloid-related imaging abnormalities

Barakos J, Sperling R, Salloway S, Jack C, Gass A, Fiebach JB, Tampieri D, Melançon D, Miaux Y, Rippon G, Black R, Lu Y, Brashear HR, Arrighi HM, Morris KA, Grundman M.

AJNR Am J Neuroradiol. 2013 Oct;34(10):1958-65. doi: 10.3174/ajnr.A3500. Epub 2013 Apr 11.

Comparison of the utility of everyday memory test and the Alzheimer's Disease Assessment Scale-Cognitive part for evaluation of mild cognitive impairment and very mild Alzheimer's disease

Adachi H, Shinagawa S, Komori K, Toyota Y, Mori T, Matsumoto T, Sonobe N, Kashibayashi T, Ishikawa T, Fukuhara R, Ikeda M.

Psychiatry Clin Neurosci. 2013 Apr;67(3):148-53. doi: 10.1111/pcn.12034.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias